+7 (701) 759 90 19
USD 412.55 EUR 468.66
RUB 5.79 CNY 58.80
News

WHO halts hydroxychloroquine and lopinavir/ritonavir hospital therapy for COVID-19

6 July 2020 13:41
Share in:
WHO halts hydroxychloroquine and lopinavir/ritonavir hospital therapy for COVID-19

MOSCOW. KAZINFORM The World Health Organization (WHO) discontinues the clinical trials of hydroxychloroquine (an antimalarial drug) and lopinavir/ritonavir (antiretroviral drugs) in therapy of hospitalized coronavirus patients, WHO said in a statement on Saturday.

Related news
Italian football club Roma sold for $700M Ship whose cargo allegedly exploded in Lebanon belongs to Russian businessman Lebanon declares emergency in Beirut

The WHO’s decision was based on the recommendation issued by the Solidarity Trial’s International Steering Committee, established by WHO to find an effective COVID-19 treatment. The solidarity trial compared the impact of the two drugs on mortality rates from the disease caused by the virus with the provided standard-of-care, TASS reports.

«These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,» the statement says.

The WHO added that the decision applies only to hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients.



Share in:
+7
Send
Employees online
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048
Editor
Raushan Alzhanova
Raushan Alzhanova
954-048
Editor
Seilkhanov Adlet
Seilkhanov Adlet
954-048

Archive